Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
NCT ID: NCT07150845
Last Updated: 2025-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
120 participants
INTERVENTIONAL
2025-08-26
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose 1
Orally administered EVO756, Dose 1
EVO756
Dose 1
Dose 2
Orally administered EVO756, Dose 2
EVO756
Dose 2
Dose 3
Orally administered EVO756, Dose 3
EVO756
Dose 3
Placebo
Placebo control
Placebo control
Placebo control
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EVO756
Dose 1
EVO756
Dose 2
EVO756
Dose 3
Placebo control
Placebo control
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Validated-Investigator's Global Assessment score of ≥3
* EASI of ≥16
* BSA of AD involvement of ≥10%
Exclusion Criteria
* Use of certain medications
* Presence of skin comorbidities or other condition(s) that may interfere with study assessments
* Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Evommune, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Dermatology Clinical Research
Fremont, California, United States
Metropolis Dermatology - Downtown Los Angeles
Los Angeles, California, United States
Skin and Beauty Center
Pasadena, California, United States
Skin Care Research, LLC
Boca Raton, Florida, United States
Driven Research, LLC
Coral Gables, Florida, United States
Skin Care Research - Hollywood Dermatology
Hollywood, Florida, United States
TrueBlue Clinical Research
Tampa, Florida, United States
DS Research
Clarksville, Indiana, United States
Equity Medical
Bowling Green, Kentucky, United States
Aesthetic and Dermatology Center
Rockville, Maryland, United States
Great Lakes Research Group, Inc.
Bay City, Michigan, United States
Revival Research Institute, LLC
Troy, Michigan, United States
Empire Dermatology
East Syracuse, New York, United States
Equity Medical
New York, New York, United States
Skin Search of Rochester, Inc.
Rochester, New York, United States
Wilmington Dermatology Center
Wilmington, North Carolina, United States
International Clinical Research - Murfreesboro
Murfreesboro, Tennessee, United States
Stryde Research
Lewisville, Texas, United States
Progressive Clinical Research
San Antonio, Texas, United States
Jordan Valley Dermatology Center
South Jordan, Utah, United States
Pacific Clinical Research Network (PCRN) - Christchurch
Christchurch Central City, Christchurch, New Zealand
Optimal Clinical Trials
Auckland, NZL, New Zealand
Optimal Clinical Trials
Auckland, NZL, New Zealand
Clinical Trials NZ Limited
Hamilton, NZL, New Zealand
Momentum Clinical Research Lower Hutt
Lower Hutt, NZL, New Zealand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EVO756-AD001
Identifier Type: -
Identifier Source: org_study_id